Sarepta Therapeutics, Inc. (SRPT) — ESG & Values Scores

Environment story

Sarepta discloses minimal direct environmental metrics. The company manufactures biologics and pharmaceuticals with inherent resource intensity. No disclosed Scope 1, 2, or 3 emissions data, renewable energy percentage, or net-zero target year are available in the 10-K. The company states it believes compliance with environmental laws is not expected to require significant capital expenditure and has not had material adverse effect on operations, but provides no affirmative evidence of decarbonization initiatives, physical infrastructure investments, or supply-chain carbon audits. No major environmental controversies, toxic-waste litigation, water-use disputes, or habitat impacts are documented in the filing. The absence of disclosed environmental commitments and metrics prevents higher scoring; the lack of controversies prevents lower scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Environmental Compliance

Company states it is subject to Occupational Safety and Health Act, Toxic Substances Control Act, Resource Conservation and Recovery Act and other federal, state and local environmental laws regarding use, manufacture, storage, handling and disposal of hazardous materials and waste products. States belief in material compliance with applicable environmental laws.

Social story

Sarepta reports 835 employees globally as of December 31, 2025; 49% hold advanced degrees; 71% engaged in R&D, 29% in SG&A. Voluntary employee turnover rate for 2025 was 9.36%. No employees covered by collective bargaining agreements; company states relations with employees are good. The company offers comprehensive total rewards including market-competitive pay, broad-based equity grants, bonuses, healthcare, retirement plans, paid time off, family leave, caregiving support, fitness subsidies, and EAP. Robust learning opportunities cited. No disclosed CEO-to-median-worker pay ratio preventing quantitative assessment. No documented union-suppression activities, strikes, or major labor litigation within 24 months. Leadership diversity metrics not disclosed in 10-K. No supply-chain human rights controversies identified related to cobalt, lithium, or other high-risk minerals. The company underwent a restructuring in July 2025 reducing workforce by approximately 36% (roughly 300 employees), which may signal labor-management tension but no formal disputes are documented. Lack of diversity disclosure and quantified pay equity data limits scoring.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Comprehensive Total Rewards Package

Company offers market-competitive pay, broad-based equity grants and bonuses, healthcare benefits, retirement savings plans (401k), paid time off and family leave, caregiving support, fitness subsidies, and an Employee Assistance Program.

Employee retention and engagement support
Learning and Development

Company provides robust learning opportunities for employees at every stage in their career and provides annual training on various topics.

Workforce development
2025 Restructuring

In July 2025, company announced restructuring to reduce operating expenses and align cost structure. Workforce reduction represented approximately 36% of workforce, with restructuring charge of $42.0 million primarily for employee termination benefits including severance.

Cost reduction; potential labor-relations friction

Governance story

Sarepta's 10-K does not disclose board composition, independence percentage, or executive share structure. No dual-class voting structure is mentioned; company appears to have single-class common stock listed on Nasdaq. No documented lobbying expenditures targeting climate deregulation or consumer-protection rollbacks are disclosed. No active antitrust proceedings, major consumer-safety fines, or SEC consent decrees are disclosed in the filing. The company faces significant regulatory scrutiny post-marketing: FDA suspended commercial shipments of ELEVIDYS in June 2025 in response to acute liver failure cases in non-ambulatory patients; voluntary hold was lifted for ambulatory patients on July 31, 2025, but non-ambulatory shipments remain suspended pending FDA guidance on sirolimus immunosuppression protocol (Cohort 8 dosing approved November 2025). On November 3, 2025, ESSENCE trial results failed primary endpoint for AMONDYS 45 and VYONDYS 53, triggering potential FDA label changes or accelerated approval revocation per FDORA. These regulatory actions are not governance violations per se but represent significant reputational and operational risk. The company has Code of Business Conduct and Ethics, Audit, Compensation, and Nominating/Corporate Governance committees with published charters, indicating baseline governance infrastructure. No shareholder proposal controversies or litigation related to governance practices are disclosed. Board independence and lobbying data unavailable; no greenwashing litigation identified.

Criticisms on file

ELEVIDYS commercial suspension and regulatory action: In June 2025, company suspended shipments of ELEVIDYS to non-ambulatory patients following two reported deaths from acute liver failure (ALF). In July 2025, disclosed another ALF death in non-ambulatory LGMD Phase I/II trial participant for SRP-9004 (not ELEVIDYS-treated). FDA requested voluntary suspension of all U.S. ELEVIDYS shipments on July 22, 2025. FDA recommended removal of hold for ambulatory patients on July 28, 2025; company resumed ambulatory shipments July 31, 2025. Non-ambulatory shipments remain suspended pending evaluation of sirolimus immunosuppression protocol (Cohort 8). Material near-term revenue impact.
Source: SRPT 10-K, MD&A Item 7, pages 83–84; Risk Factors section; Note 23 Commitments and Contingencies
ESSENCE trial primary endpoint failure: On November 3, 2025, company announced topline results from ESSENCE confirmatory trial for AMONDYS 45 and VYONDYS 53 failed to show statistical significance on primary endpoint. Company stated intent to discuss potential pathway forward with FDA. Per FDORA, FDA has expanded expedited withdrawal procedures for accelerated approvals if post-approval studies fail to verify clinical benefit.
Source: SRPT 10-K, MD&A Item 7, page 76; Risk Factors section
Inventory valuation and quality issues: In 2025, company recorded $165.3 million in inventory write-downs for excess and obsolete inventory, primarily ELEVIDYS and PMO products, reflecting manufacturing batches not meeting quality specifications and forecasted demand misalignment. Additional $24.4 million expected to be reimbursed by Roche. Significant quality-control and demand-forecasting challenges.
Source: SRPT 10-K, MD&A Item 7, page 77; Critical Accounting Policies section

Disclosed initiatives

Code of Business Conduct and Ethics

Company has adopted Code of Business Conduct and Ethics available on website; changes disclosed within four business days per SEC rules.

Ethics and compliance framework
Board Committee Structure

Company has Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee with published charters available on website.

Corporate governance oversight
Disclosure Controls

Company uses website to disclose material non-public information and comply with Regulation FD obligations.

Investor transparency

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Sarepta Therapeutics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Sarepta Therapeutics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)